Skip to main
CDTX
CDTX logo

Cidara Therapeutics (CDTX) Stock Forecast & Price Target

Cidara Therapeutics (CDTX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 59%
Buy 35%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Cidara Therapeutics Inc. is positioned favorably due to the recent report of a strong influenza season, which could enhance the uptake of its clinical-stage asset, CD388, aimed at influenza prophylaxis. The company has also secured significant funding of $240 million in April 2024, enabling accelerated clinical development and leveraging their existing expertise with CD388 to further advance this asset. Additionally, the company's proprietary Cloudbreak platform, which includes DFCs targeting a range of diseases, positions Cidara favorably in the competitive landscape, potentially transforming treatment and preventative methods for serious diseases.

Bears say

Cidara Therapeutics, Inc. reported a substantial net loss of $52.4 million in 4Q24, indicating ongoing financial difficulties and a lack of profitability. The company's lead candidate, CD388, while demonstrating potent effects against influenza, suffers from poor oral bioavailability and fast renal clearance, raising concerns about its clinical viability. Additionally, the potential inability to secure acceptable partnerships further jeopardizes the prospects for successful commercialization, particularly in an environment where vaccine efficacy is heavily reliant on proper strain matching.

Cidara Therapeutics (CDTX) has been analyzed by 17 analysts, with a consensus rating of Buy. 59% of analysts recommend a Strong Buy, 35% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cidara Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cidara Therapeutics (CDTX) Forecast

Analysts have given Cidara Therapeutics (CDTX) a Buy based on their latest research and market trends.

According to 17 analysts, Cidara Therapeutics (CDTX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cidara Therapeutics (CDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.